-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Lara C. Pullen, PhD, is a freelance medical writer in Chicago. New results indicate that while many adults with acute myeloid leukemia (AML) experience some decline in physical health, patients can be grouped into four distinct trajectories of physical well-being (PWB). Marielle Jensen-Battaglia, PT, DPT, a licensed physical therapist and epidemiology PhD candidate at the University of Rochester Medical Center in New York, and colleagues published the results of the first study to explore risk factors
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Transplant without salvage: cut out the middleman - 12 day(s) ago
In this issue of The Lancet Haematology, Matthias Stelljes and colleagues1 present a compelling exploration of an approach to allogeneic haematopoietic stem-cell transplantation (HSCT) in patients at high risk of relapse or induction-refractory acute myeloid leukaemia. This concept is in stark contrast with the long-upheld orthodoxy of using varying regimens of salvage chemotherapy to induce remission or a morphological leukaemia-free state before transplantation.2 These approaches, while considered to be the standard of care in most institutions, are associated with substantial morbidity, particularly when conventional chemotherapy is used.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 18 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 20 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 23 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML - 25 day(s) ago
Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
.@us_fda Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML #leusm https://t.co/g554JT9Hq4